Back to search

Article

Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve disease

2025-12-19

Abstract excerpt

<h4>BACKGROUND</h4> Calcific aortic valve disease (CAVD) compromises valve compliance and cardiac hemodynamics leading to aortic stenosis (AS) and cardiovascular dysfunction. With treatment for severe AS limited to valve replacement and no effective pharmacotherapies, new interventions are urgently needed for patients. This study evaluated pemafibrate, a selective peroxisome proliferator-activated receptor alpha...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7db2c5de-b540-53e8-a696-8ecd95fa4a50
DOI
10.64898/2025.12.17.694919
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve diseaseDOI 10.64898/2025.12.17.694919
Select a neighboring publication to make it the new centre.